Nabriva Therapeutics's revenue per share for the
three
months ended in Jun. 2023 was $0.80.
Nabriva Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2023 was $9.74.
Warning Sign:
Nabriva Therapeutics PLC revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Nabriva Therapeutics was -34.60% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -20.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Nabriva Therapeutics's Revenue per Share or its related term are showing as below:
NBRVF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.2 Med: -20.65 Max: -20.1
Current: -20.1
During the past 10 years, Nabriva Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was -20.10% per year. The lowest was -21.20% per year. And the median was -20.65% per year.
NBRVF's 3-Year Revenue Growth Rate is ranked worse than 77.92% of 770
companies
in the Biotechnology industry
Industry Median: 5.4
vs NBRVF: -20.10
Nabriva Therapeutics Revenue per Share Historical Data
The historical data trend for Nabriva Therapeutics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nabriva Therapeutics's Revenue per Share
For the Biotechnology subindustry, Nabriva Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nabriva Therapeutics's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Nabriva Therapeutics's PS Ratio falls into.
Nabriva Therapeutics Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Nabriva Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2022 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.74
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nabriva Therapeutics (OTCPK:NBRVF) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Nabriva Therapeutics Revenue per Share Related Terms
Thank you for viewing the detailed overview of Nabriva Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Nabriva Therapeutics (Nabriva Therapeutics) Business Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBRVF has been successfully added to your 